Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.

Trial Profile

Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Danusertib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 29 Sep 2015 Status changed from recruiting to active, no longer recruiting. As this trial was started on 2 Feb 2007 and its prospective end date is also passed more over according to the results published in the annals of oncology total 223 patients were enrolled which are close to target accrual (~ planned accrual 232) , hence it seems that trial is closed to accrual.
    • 03 Jul 2012 Additional locations (Belgium, France, Germany, Netherlands, United Kingdom) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top